BiomX (PHGE)
Market Price (8/21/2026): $0.14 | Market Cap: $0.4 MilSector: Industrials | Industry: Aerospace & Defense
BiomX (PHGE)
Market Price (8/21/2026): $0.14Market Cap: $0.4 MilSector: IndustrialsIndustry: Aerospace & Defense
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -320% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -137%, 3Y Excs Rtn is -172% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 19% | Penny stockMkt Price is 0.1 Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11526% High stock price volatilityVol 12M is 1916% Key risksPHGE key risks include [1] a critical cash shortage highlighted by a "going concern" qualification from its auditors, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -320% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -137%, 3Y Excs Rtn is -172% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 19% |
| Penny stockMkt Price is 0.1 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11526% |
| High stock price volatilityVol 12M is 1916% |
| Key risksPHGE key risks include [1] a critical cash shortage highlighted by a "going concern" qualification from its auditors, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/11/2026
BiomX (PHGE) stock has lost about 85% since 4/30/2026 because of the following key factors:
1. Discontinuation of Key Clinical Trial: BiomX's stock was significantly impacted by the discontinuation of its Phase 2b BX004 trial in cystic fibrosis in December 2025, which was previously expected to report topline results in fiscal Q2 2026. The decision to halt the trial followed an internal analysis and Data Monitoring Committee (DMC) feedback regarding unexpectedly high rates of adverse events and the projected resources required to safely proceed with an alternative strategy, thereby removing a critical near-term value driver from its biotech pipeline.
2. Severe Financial Deterioration and Shareholder Dilution: The company experienced severe financial distress, evidenced by a NYSE American notice of non-compliance in March 2026 due to falling below stockholders' equity minimums. This was further highlighted by the fiscal Q4 2025 earnings reported on July 10, 2026, which showed a deep earnings per share (EPS) miss of -$8.17 against a consensus estimate of -$4.70, a negative surprise of 73.75%, and no reported revenue for the quarter. This precarious financial state, coupled with a reported negative levered free cash flow of $23 million over the last twelve months, was compounded by substantial shareholder dilution, including a 497% increase in shares outstanding over the past year due to equity raises and share issuances for acquisitions.
Show more
BiomX (PHGE) stock has lost about 85% since 4/30/2026 because of the following key factors:
1. Discontinuation of Key Clinical Trial: BiomX's stock was significantly impacted by the discontinuation of its Phase 2b BX004 trial in cystic fibrosis in December 2025, which was previously expected to report topline results in fiscal Q2 2026. The decision to halt the trial followed an internal analysis and Data Monitoring Committee (DMC) feedback regarding unexpectedly high rates of adverse events and the projected resources required to safely proceed with an alternative strategy, thereby removing a critical near-term value driver from its biotech pipeline.
2. Severe Financial Deterioration and Shareholder Dilution: The company experienced severe financial distress, evidenced by a NYSE American notice of non-compliance in March 2026 due to falling below stockholders' equity minimums. This was further highlighted by the fiscal Q4 2025 earnings reported on July 10, 2026, which showed a deep earnings per share (EPS) miss of -$8.17 against a consensus estimate of -$4.70, a negative surprise of 73.75%, and no reported revenue for the quarter. This precarious financial state, coupled with a reported negative levered free cash flow of $23 million over the last twelve months, was compounded by substantial shareholder dilution, including a 497% increase in shares outstanding over the past year due to equity raises and share issuances for acquisitions.
Show more
Updated on 8/11/2026
BiomX (PHGE) stock has lost about 85% since 4/30/2026 because of the following key factors:
1. Discontinuation of Key Clinical Trial: BiomX's stock was significantly impacted by the discontinuation of its Phase 2b BX004 trial in cystic fibrosis in December 2025, which was previously expected to report topline results in fiscal Q2 2026. The decision to halt the trial followed an internal analysis and Data Monitoring Committee (DMC) feedback regarding unexpectedly high rates of adverse events and the projected resources required to safely proceed with an alternative strategy, thereby removing a critical near-term value driver from its biotech pipeline.
2. Severe Financial Deterioration and Shareholder Dilution: The company experienced severe financial distress, evidenced by a NYSE American notice of non-compliance in March 2026 due to falling below stockholders' equity minimums. This was further highlighted by the fiscal Q4 2025 earnings reported on July 10, 2026, which showed a deep earnings per share (EPS) miss of -$8.17 against a consensus estimate of -$4.70, a negative surprise of 73.75%, and no reported revenue for the quarter. This precarious financial state, coupled with a reported negative levered free cash flow of $23 million over the last twelve months, was compounded by substantial shareholder dilution, including a 497% increase in shares outstanding over the past year due to equity raises and share issuances for acquisitions.
3. Abrupt Strategic Pivot: BiomX underwent a fundamental and abrupt shift in its business strategy, transitioning from a clinical-stage company focused on phage therapies for chronic diseases to a company centered on defense and security technologies. This pivot was underscored by acquisitions such as Zorronet in April 2026 (with updated terms and share issuance in July 2026) and a 10% stake in Motomea in August 2026, which develops electric motor testing systems for drones. This significant change in direction likely led to a re-evaluation by investors and a loss of confidence from those who invested based on its original biotech focus.
Show less
BiomX (PHGE) stock has lost about 85% since 4/30/2026 because of the following key factors:
1. Discontinuation of Key Clinical Trial: BiomX's stock was significantly impacted by the discontinuation of its Phase 2b BX004 trial in cystic fibrosis in December 2025, which was previously expected to report topline results in fiscal Q2 2026. The decision to halt the trial followed an internal analysis and Data Monitoring Committee (DMC) feedback regarding unexpectedly high rates of adverse events and the projected resources required to safely proceed with an alternative strategy, thereby removing a critical near-term value driver from its biotech pipeline.
2. Severe Financial Deterioration and Shareholder Dilution: The company experienced severe financial distress, evidenced by a NYSE American notice of non-compliance in March 2026 due to falling below stockholders' equity minimums. This was further highlighted by the fiscal Q4 2025 earnings reported on July 10, 2026, which showed a deep earnings per share (EPS) miss of -$8.17 against a consensus estimate of -$4.70, a negative surprise of 73.75%, and no reported revenue for the quarter. This precarious financial state, coupled with a reported negative levered free cash flow of $23 million over the last twelve months, was compounded by substantial shareholder dilution, including a 497% increase in shares outstanding over the past year due to equity raises and share issuances for acquisitions.
3. Abrupt Strategic Pivot: BiomX underwent a fundamental and abrupt shift in its business strategy, transitioning from a clinical-stage company focused on phage therapies for chronic diseases to a company centered on defense and security technologies. This pivot was underscored by acquisitions such as Zorronet in April 2026 (with updated terms and share issuance in July 2026) and a 10% stake in Motomea in August 2026, which develops electric motor testing systems for drones. This significant change in direction likely led to a re-evaluation by investors and a loss of confidence from those who invested based on its original biotech focus.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -83.6% change in PHGE stock from 4/30/2026 to 8/20/2026 was primarily driven by a -36.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302026 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.85 | 0.14 | -83.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 3 | -36.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 8/20/2026| Return | Correlation | |
|---|---|---|
| PHGE | -83.6% | |
| Market (SPY) | 6.1% | 19.7% |
| Sector (XLI) | 3.0% | 20.5% |
Fundamental Drivers
The -97.6% change in PHGE stock from 1/31/2026 to 8/20/2026 was primarily driven by a -36.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312026 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.72 | 0.14 | -97.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 3 | -36.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 8/20/2026| Return | Correlation | |
|---|---|---|
| PHGE | -97.6% | |
| Market (SPY) | 10.5% | 6.4% |
| Sector (XLI) | 9.0% | 9.6% |
Fundamental Drivers
The -98.1% change in PHGE stock from 7/31/2025 to 8/20/2026 was primarily driven by a -53.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.40 | 0.14 | -98.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 3 | -53.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 8/20/2026| Return | Correlation | |
|---|---|---|
| PHGE | -98.1% | |
| Market (SPY) | 21.7% | 8.1% |
| Sector (XLI) | 19.5% | 8.5% |
Fundamental Drivers
The -99.8% change in PHGE stock from 7/31/2023 to 8/20/2026 was primarily driven by a -93.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312023 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 81.70 | 0.14 | -99.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 3 | -93.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2023 to 8/20/2026| Return | Correlation | |
|---|---|---|
| PHGE | -99.8% | |
| Market (SPY) | 72.5% | 4.5% |
| Sector (XLI) | 69.6% | 5.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PHGE Return | -75% | -88% | 50% | -74% | -87% | -93% | -100% |
| Peers Return | 14% | -60% | 11% | -48% | 56% | 5% | -57% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| PHGE Win Rate | 17% | 33% | 42% | 25% | 17% | 25% | |
| Peers Win Rate | 40% | 33% | 43% | 37% | 58% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| PHGE Max Drawdown | -83% | -93% | -58% | -93% | -99% | -98% | |
| Peers Max Drawdown | -60% | -72% | -63% | -66% | -71% | -52% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ARMP, MCRB, NTLA, EDIT, BEAM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/20/2026 (YTD)
How Low Can It Go
| Event | PHGE | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -35.5% | -9.5% |
| % Gain to Breakeven | 55.0% | 10.5% |
| Time to Breakeven | 96 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.3% | -6.7% |
| % Gain to Breakeven | 33.9% | 7.1% |
| Time to Breakeven | 29 days | 31 days |
In The Past
BiomX's stock fell -35.5% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 55.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PHGE | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -35.5% | -9.5% |
| % Gain to Breakeven | 55.0% | 10.5% |
| Time to Breakeven | 96 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -25.3% | -6.7% |
| % Gain to Breakeven | 33.9% | 7.1% |
| Time to Breakeven | 29 days | 31 days |
In The Past
BiomX's stock fell -35.5% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 55.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About BiomX (PHGE)
BiomX Inc. (PHGE) is a clinical-stage biotechnology company that specializes in developing innovative therapies using natural and engineered bacteriophages, often referred to as phages. Phages are a type of virus that specifically target and kill harmful bacteria without affecting human cells, offering a highly precise approach to treating various diseases. The company's core mission is to leverage this technology to address chronic conditions and diseases by eliminating specific problematic bacterial strains.
BiomX's product pipeline is diversified, targeting several significant medical needs. Its most advanced product, BX004, is a phage therapy currently in Phase 1b/2a clinical trials for cystic fibrosis patients who suffer from chronic Pseudomonas aeruginosa respiratory infections. The company is also developing BX005, a topical phage cocktail in Phase 1/2 for Staphylococcus aureus bacteria, which is associated with skin conditions like atopic dermatitis. Additionally, BX003 is an orally administered phage cocktail in Phase 1b/2a, aimed at targeting specific gut bacteria implicated in inflammatory bowel diseases (IBD) and primary sclerosing cholangitis (PSC).
Beyond these programs, BiomX is exploring a novel approach for colorectal cancer with a program utilizing engineered phages. These phages are designed to be administered intravenously to target Fusobacterium nucleatum bacteria, which are often found within tumor microenvironments. The company's overall market focus is on developing precision antibacterial therapies for patients suffering from chronic infections, inflammatory conditions, and certain cancers, addressing significant unmet medical needs in these areas.
AI Analysis | Feedback
BiomX is like Moderna, but instead of mRNA vaccines, they use viruses (phages) to precisely kill harmful bacteria.
BiomX is like Crispr Therapeutics, but instead of editing human genes, they use viruses to precisely eliminate specific harmful bacteria.
AI Analysis | Feedback
- BX004: A phage therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa respiratory infections.
- BX005: A topical phage cocktail targeting Staphylococcus aureus for atopic dermatitis.
- BX003: An orally administered phage cocktail for inflammatory bowel diseases and primary sclerosing cholangitis.
- Colorectal Cancer Program: An engineered phage therapy targeting Fusobacterium nucleatum bacteria within the tumor microenvironment for colorectal cancer.
AI Analysis | Feedback
BiomX Inc. (PHGE) is a clinical-stage microbiome company developing therapeutic products that are currently in various phases of clinical trials. As such, it does not yet have commercially approved products or major customers that purchase its therapies or services. Its products are investigational drugs targeting specific patient populations (e.g., CF patients, IBD and PSC patients, individuals with atopic dermatitis, or colorectal cancer patients), but these products are not yet available for sale.
AI Analysis | Feedback
null
AI Analysis | Feedback
Michael Oster, Chief Executive Officer
Michael Oster brings over 25 years of experience in corporate finance, mergers and acquisitions (M&A), and complex international transactions, having held senior leadership roles in both public and private companies. He currently serves as Chief Executive Officer and a board member of Saffron Tech Ltd., an agritech company, and as a board member of BladeRanger Ltd., a publicly traded Israeli innovator in advanced drone payload systems. Earlier in his career, he was the Senior Vice President of Mergers and Acquisitions at Alon USA Energy, Inc., where he led numerous strategic transactions.
David Rokach, Chief Financial Officer
David Rokach possesses over two decades of experience in finance, investment management, and corporate leadership. He is responsible for BiomX’s financial strategy, capital markets activities, accounting, and investor relations. Since 2024, he has been a member of the board of directors of T3 Defense Inc. Previously, he held Chief Executive Officer positions at Newcom Finance and Granit Investment Company, and he has provided strategic and financial advisory services to corporations and hedge funds.
AI Analysis | Feedback
The key risks to BiomX (PHGE) are primarily centered around its financial viability and the success of its clinical development pipeline.
- Clinical Trial Failures and Regulatory Hurdles: A significant risk for BiomX stems from the inherent uncertainties of pharmaceutical research and development and the stringent regulatory approval process. In a major setback, BiomX announced the discontinuation of its Phase 2b clinical trial for nebulized phage therapy BX004, intended for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, in December 2025. This decision followed an internal analysis and recommendations from an independent Data Monitoring Committee due to unexpectedly high rates of adverse events. Prior to this, the U.S. portion of the BX004 Phase 2b study was already under an FDA clinical hold, albeit related to a third-party nebulizer and not the drug product itself, causing delays. The inability to successfully advance its primary drug candidates through clinical trials and obtain regulatory approval poses a critical threat to the company's future.
- Going Concern Risk and Insufficient Funding: BiomX faces substantial doubt about its ability to continue as a going concern due to severe liquidity pressure. As of September 30, 2025, the company reported a cash balance of $8.1 million, which was estimated to be sufficient to fund operations only into the first quarter of 2026. This necessitates securing additional financing or entering into partnerships, which could lead to significant shareholder dilution. The financial distress is so acute that in December 2025, BiomX initiated insolvency proceedings for its Israeli subsidiary, BiomX Ltd., which previously housed core operations and contributed to accumulated debts of approximately NIS 11 million (around $3.4 million).
- Lack of Revenue Generation: As a clinical-stage biotechnology company, BiomX has no approved products on the market and has not generated any revenue from product sales. The company operates at a net loss, with significant investment in research and development. This pre-revenue status means that BiomX is entirely reliant on external funding to advance its pipeline, making it highly vulnerable to the success of its clinical programs and its ability to raise capital.
AI Analysis | Feedback
null
AI Analysis | Feedback
BiomX (PHGE) targets several significant addressable markets with its phage technology products:
- BX004 for Cystic Fibrosis (CF) with Pseudomonas aeruginosa respiratory infections: The global cystic fibrosis therapeutics market was valued at $12.9 billion in 2024 and is projected to reach $32.3 billion by 2034. The global Pseudomonas aeruginosa treatment market was valued at $5.84 billion in 2024 and is projected to reach $11.81 billion by 2032. Specifically for BX004, the U.S. market in CF patients with chronic lung infections caused by Pseudomonas aeruginosa is estimated to be over $1 billion.
- BX005 for Atopic Dermatitis targeting Staphylococcus aureus: The global atopic dermatitis drugs market was valued at approximately $12.1 billion in 2024 and is estimated to grow to $31 billion by 2034. Another source indicates the global atopic dermatitis treatment market was valued at $17.05 billion in 2024 and is expected to reach $32.04 billion by 2032.
- BX003 for Inflammatory Bowel Diseases (IBD) and Primary Sclerosing Cholangitis (PSC): The global inflammatory bowel disease treatment market is expected to be valued at approximately $25.5 billion in 2025 and is estimated to reach $36.4 billion by 2032. The global primary sclerosing cholangitis (PSC) market size was valued at approximately $800 million in 2023 and is projected to grow to $1.2 billion by 2032.
- Colorectal Cancer (CRC) program targeting Fusobacterium nucleatum: The global colorectal cancer therapeutics market size was valued at $12.79 billion in 2024 and is expected to reach approximately $19.95 billion by 2034.
AI Analysis | Feedback
BiomX Inc. (PHGE), a clinical-stage microbiome company, is not expected to generate significant commercial revenue within the immediate 2-3 year timeframe (2026-2028), as analysts currently forecast $0 revenue for 2026 and 2027, with some projections of approximately $11.2 million in 2028. Therefore, the primary drivers of future revenue growth for BiomX are centered on the successful advancement of its pipeline through clinical development and regulatory milestones, which would pave the way for eventual product commercialization.
Here are the expected drivers of future revenue growth for BiomX over the next 2-3 years:
* Advancement of Lead Clinical Programs Through Key Milestones: The successful progression of BiomX's lead product candidates, BX004 and BX011/BX211, through significant clinical trial readouts and positive regulatory interactions, is paramount for future revenue growth. This includes the anticipated topline results for the Phase 2b clinical trial of BX004, a phage therapy for cystic fibrosis patients with *Pseudomonas aeruginosa* respiratory infections, expected in Q1 2026. Additionally, leveraging the positive Phase 2 results for BX211 in diabetic foot osteomyelitis (DFO) and the clear clinical development path for BX011 in diabetic foot infections (DFI) will be crucial for moving these programs closer to market. Favorable feedback from regulatory bodies like the FDA, including supportive guidance for potential Phase 3 development, significantly de-risks these programs and enhances their commercial prospects.
* Progression of Earlier-Stage Pipeline Candidates: Expanding and advancing other programs within the pipeline, such as BX003 for inflammatory bowel diseases (IBD) and primary sclerosing cholangitis (PSC), and the colorectal cancer program utilizing engineered phage, will contribute to the company's long-term revenue potential. Even if these programs do not reach commercialization within the next 2-3 years, their successful progression into later-stage clinical development or new indications would broaden BiomX's future market opportunities and increase its overall valuation.
* Strategic Partnerships and Non-Dilutive Funding: As a pre-revenue, clinical-stage company, securing strategic collaborations with larger pharmaceutical entities and obtaining additional non-dilutive funding are vital for financing ongoing research and development (R&D) and clinical trials. Such partnerships can provide upfront payments, milestone payments upon achieving specific development or regulatory goals, and potential royalty agreements upon commercialization, thereby directly or indirectly supporting future revenue generation. The significant non-dilutive funding received from the U.S. Defense Health Agency for the BX211 program exemplifies this driver.
AI Analysis | Feedback
Share Issuance
- In March 2026, BiomX shareholders approved the authorization to issue shares of Common Stock underlying Series Y convertible preferred stock and accompanying warrants, exceeding 19.99% of the existing Common Stock outstanding prior to the transaction.
- In December 2025, the company finalized agreements for a private investment in public equity (PIPE) that would result in approximately $3.0 million in gross proceeds through the issuance of Series Y Convertible Preferred Stock and warrants.
- In November 2025, BiomX implemented a one-for-nineteen reverse stock split, which reduced the number of outstanding shares from approximately 29 million to around 1.5 million.
Inbound Investments
- In December 2025, BiomX secured approximately $3 million through a private investment in public equity (PIPE) from certain investors.
- In January 2026, Pyu Pyu Capital acquired a 19.99% stake in BiomX, as disclosed in a 13D filing.
- In February 2025, the company raised $12 million in a financing round, which was led by Deerfield Management Company and included significant participation from the Cystic Fibrosis Foundation, along with contributions from Nantahala Capital and other investors.
Capital Expenditures
- For the last 12 months, BiomX's capital expenditures were reported as -$2,000, indicating minimal spending in this area.
- As a clinical-stage biotechnology company, BiomX's investing cash flow is minimal, with its primary focus being on research and development rather than significant capital expenditures.
Peer Outperformance in Aerospace & Defense
PHGE has trailed 96% of its 54 Aerospace & Defense peers over 5Y. Aerospace & Defense ranks 4th of 23 industries in Industrials by median 5Y return.
Share of Aerospace & Defense constituents that PHGE has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
0%
of 70 industry peers · -98.6% return
3Y
5%
of 60 industry peers · -99.8% return
5Y
4%
of 54 industry peers · -100.0% return
No Aerospace & Defense peer with a comparable growth profile has beaten PHGE by more than 20pp over 5Y.
Median price return by industry across the Industrials sector, ranked by 5Y. Aerospace & Defense is PHGE's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Construction & Engineering | 31 | 29.0% | 130.0% | 210.1% | CDNL 3150% · STRL 2271% · FIX 2195% |
| Marine Transportation | 4 | 65.3% | 63.9% | 164.2% | MATX 216% · KEX 164% · SFL 164% |
| Construction Machinery & Heavy Transportation Equipment | 13 | 12.8% | 63.1% | 123.5% | CAT 334% · ALSN 272% · WAB 251% |
| Aerospace & Defense ← | 55 | 14.2% | 69.9% | 83.1% | DFNS 2442% · ATI 1079% · FTAI 931% |
| Passenger Ground Transportation | 3 | -2.7% | 56.8% | 68.8% | UBER 97% · CAR 69% · LYFT -62% |
| Industrial Machinery & Supplies & Components | 71 | 10.6% | 55.4% | 54.0% | CRS 1511% · PSIX 843% · GHM 739% |
| Rail Transportation | 7 | 37.7% | 73.2% | 46.8% | FSTR 119% · CSX 62% · UNP 52% |
| Cargo Ground Transportation | 16 | 45.8% | 12.0% | 45.7% | XPO 281% · R 274% · CVLG 222% |
| Trading Companies & Distributors | 18 | 5.6% | 34.8% | 44.1% | DXPE 532% · AIT 307% · URI 245% |
| Diversified Support Services | 34 | 12.0% | 33.4% | 40.4% | LIME 4787% · TH 408% · WLFC 355% |
| Electrical Components & Equipment | 40 | 24.7% | 44.6% | 31.5% | POWL 2445% · BE 912% · VRT 882% |
| Building Products | 33 | -4.1% | 16.6% | 29.2% | GFF 423% · LMB 423% · PPIH 287% |
| Industrial Conglomerates | 17 | 23.4% | 26.6% | 10.3% | RCMT 808% · TTI 182% · CSW 151% |
| Office Services & Supplies | 10 | 14.7% | 27.3% | 4.2% | TILE 199% · PBI 168% · EBF 57% |
| Environmental & Facilities Services | 28 | -8.1% | 16.9% | 3.3% | CECO 904% · ADUR 652% · NVRI 302% |
| Research & Consulting Services | 13 | -6.9% | -18.4% | -3.8% | HURN 226% · CRAI 98% · GRNQ 80% |
| Agricultural & Farm Machinery | 17 | -3.3% | -10.5% | -17.6% | BLBD 196% · DE 89% · GENC 66% |
| Data Processing & Outsourced Services | 6 | -30.7% | -9.3% | -25.1% | EXLS 55% · BR 12% · G -24% |
| Passenger Airlines | 11 | 8.8% | -8.6% | -26.1% | LTM 2372% · UAL 154% · SKYW 151% |
| Human Resource & Employment Services | 21 | 12.6% | -19.8% | -35.3% | BBSI 88% · ADP 47% · KFY 39% |
| Air Freight & Logistics | 12 | -13.3% | -25.2% | -36.6% | CHRW 83% · FDX 69% · EXPD 61% |
| Security & Alarm Services | 10 | -32.3% | -17.2% | -47.1% | CIX 121% · MG 101% · BCO 56% |
| Airport Services | 3 | -68.1% | -69.6% | -58.7% | JOBY -24% · ASLE -59% · UP -100% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.50 |
| Mkt Cap | 0.3 |
| Rev LTM | 24 |
| Op Inc LTM | -81 |
| FCF LTM | -86 |
| FCF 3Y Avg | -132 |
| CFO LTM | -86 |
| CFO 3Y Avg | -130 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 20.8% |
| Rev Chg 3Y Avg | 75.3% |
| Rev Chg Q | -46.2% |
| QoQ Delta Rev Chg LTM | 8.3% |
| Op Inc Chg LTM | 23.1% |
| Op Inc Chg 3Y Avg | 0.3% |
| Op Mgn LTM | -477.0% |
| Op Mgn 3Y Avg | -344.8% |
| QoQ Delta Op Mgn LTM | 18.4% |
| CFO/Rev LTM | -418.8% |
| CFO/Rev 3Y Avg | -339.4% |
| FCF/Rev LTM | -421.2% |
| FCF/Rev 3Y Avg | -346.4% |
Price Behavior
Price Behavior
| Market Price | $0.14 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/13/2019 | |
| Distance from 52W High | -98.8% | |
| 50 Days | 200 Days | |
| DMA Price | $0.28 | $2.62 |
| DMA Trend | down | down |
| Distance from DMA | -50.5% | -94.7% |
| 3M | 1YR | |
| Volatility | 232.8% | 1,920.2% |
| Downside Capture | 628.75 | 1084.68 |
| Upside Capture | -207.69 | 392.40 |
| Correlation (SPY) | 15.6% | 8.3% |
PHGE Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.29 | 0.84 | 3.94 | 1.05 | 12.27 | 3.31 |
| Up Beta | 4.72 | 5.85 | 5.80 | -0.79 | 17.50 | 2.60 |
| Down Beta | -1.92 | 0.20 | -0.24 | -2.92 | -0.60 | 0.31 |
| Up Capture | -440% | -414% | -22% | -92% | 2366% | 200% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 5 | 10 | 17 | 34 | 98 | 310 |
| Down Capture | 402% | 385% | 449% | 284% | 200% | 112% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 15 | 30 | 43 | 88 | 150 | 426 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PHGE | |
|---|---|---|---|---|
| PHGE | -98.7% | 1,916.4% | 0.81 | - |
| Sector ETF (XLI) | 20.1% | 17.1% | 0.90 | 8.6% |
| Equity (SPY) | 20.3% | 12.9% | 1.16 | 8.2% |
| Gold (GLD) | 36.2% | 28.7% | 1.07 | 0.5% |
| Commodities (DBC) | 44.1% | 20.2% | 1.69 | -3.8% |
| Real Estate (VNQ) | 13.3% | 13.8% | 0.66 | 7.0% |
| Bitcoin (BTCUSD) | -38.8% | 43.2% | -1.01 | -1.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PHGE | |
|---|---|---|---|---|
| PHGE | -82.0% | 867.7% | 0.34 | - |
| Sector ETF (XLI) | 12.9% | 17.6% | 0.57 | 4.7% |
| Equity (SPY) | 12.8% | 17.2% | 0.57 | 3.7% |
| Gold (GLD) | 20.4% | 18.6% | 0.89 | 1.2% |
| Commodities (DBC) | 10.2% | 19.6% | 0.40 | -1.1% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.02 | 2.9% |
| Bitcoin (BTCUSD) | 9.3% | 52.7% | 0.36 | 0.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PHGE | |
|---|---|---|---|---|
| PHGE | -61.7% | 714.3% | 0.27 | - |
| Sector ETF (XLI) | 13.8% | 20.0% | 0.61 | 3.5% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 3.1% |
| Gold (GLD) | 12.4% | 16.2% | 0.63 | 1.2% |
| Commodities (DBC) | 8.1% | 18.1% | 0.37 | -0.7% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 2.4% |
| Bitcoin (BTCUSD) | 61.0% | 66.1% | 1.01 | 0.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 8/11/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | -1.9% | -96.1% | -68.7% |
| 8/13/2025 | -11.7% | -2.5% | -9.4% |
| 5/15/2025 | 3.1% | -2.9% | -25.2% |
| 3/25/2025 | -7.2% | -11.8% | -6.2% |
| 11/14/2024 | 3.6% | -29.7% | -12.4% |
| 4/3/2024 | -8.9% | -8.6% | 15.7% |
| 11/14/2023 | -1.2% | -5.2% | -25.0% |
| 8/9/2023 | -9.3% | -10.2% | -7.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 1 | 3 |
| # Negative | 14 | 18 | 16 |
| Median Positive | 3.1% | 0.3% | 15.7% |
| Median Negative | -6.3% | -11.0% | -21.8% |
| Max Positive | 7.2% | 0.3% | 25.4% |
| Max Negative | -16.4% | -96.1% | -68.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | -1.9% | -96.1% | -68.7% |
| 8/13/2025 | -11.7% | -2.5% | -9.4% |
| 5/15/2025 | 3.1% | -2.9% | -25.2% |
| 3/25/2025 | -7.2% | -11.8% | -6.2% |
| 11/14/2024 | 3.6% | -29.7% | -12.4% |
| 4/3/2024 | -8.9% | -8.6% | 15.7% |
| 11/14/2023 | -1.2% | -5.2% | -25.0% |
| 8/9/2023 | -9.3% | -10.2% | -7.1% |
| 5/15/2023 | 7.2% | 0.3% | 25.4% |
| 3/29/2023 | 2.2% | -11.8% | -10.4% |
| 11/9/2022 | -4.4% | -23.5% | -33.8% |
| 8/10/2022 | -6.4% | -7.5% | -31.6% |
| 5/11/2022 | -6.1% | -13.9% | -31.1% |
| 11/15/2021 | -4.8% | -20.1% | -33.7% |
| 8/16/2021 | -7.7% | -6.4% | -18.7% |
| 5/24/2021 | 1.6% | -1.0% | -10.6% |
| 3/31/2021 | -1.5% | -12.3% | -5.0% |
| 11/12/2020 | -0.2% | -1.2% | 5.9% |
| 8/13/2020 | -16.4% | -23.9% | -25.3% |
| SUMMARY STATS | |||
| # Positive | 5 | 1 | 3 |
| # Negative | 14 | 18 | 16 |
| Median Positive | 3.1% | 0.3% | 15.7% |
| Median Negative | -6.3% | -11.0% | -21.8% |
| Max Positive | 7.2% | 0.3% | 25.4% |
| Max Negative | -16.4% | -96.1% | -68.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/20/2026 | 10-Q |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/25/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-Q |
| 12/31/2023 | 04/04/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/20/2026 | 10-Q |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/25/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-Q |
| 12/31/2023 | 04/04/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/16/2021 | 10-Q |
| 03/31/2021 | 05/24/2021 | 10-Q |
| 12/31/2020 | 03/31/2021 | 10-K |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 03/26/2020 | 10-K |
| 09/30/2019 | 10/16/2019 | 10-Q |
| 06/30/2019 | 08/21/2019 | 10-K |
| 03/31/2019 | 05/10/2019 | 10-Q |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3182026 | 5.00 | 530,000 | Form | |||
| 2 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3182026 | 5.00 | 450,000 | Form | |||
| 3 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3132026 | 5.00 | 370,000 | Form | |||
| 4 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3132026 | 5.00 | 300,000 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3182026 | 5.00 | 530,000 | Form | |||
| 2 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3182026 | 5.00 | 450,000 | Form | |||
| 3 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3132026 | 5.00 | 370,000 | Form | |||
| 4 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3132026 | 5.00 | 300,000 | Form |
Industry Resources
| Industrials Resources |
| IndustryWeek |
| Manufacturing.net |
| Aviation Week |
| Aerospace & Defense Resources |
| Defense News |
| FlightGlobal |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/20/2026